Loading market dashboard
Vera Therapeutics, Inc.
VERAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 28,800 shares of Class A common stock and restricted stock units (RSUs) underlying 14,150 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
You can argue about almost every line in a NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) earnings release.
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgAN
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approval Strong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch BRISBANE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2026.
BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026.
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
JPMorgan Chase and Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) by 73.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,365 shares of the company's stock after selling 228,182 shares during the period. JPMorgan
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.
BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera's new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D.
Shares of Vera Therapeutics, Inc. (NASDAQ: VERA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the
Integral Health bought 100,000 Vera Therapeutics shares for an estimated $3.55 million in the fourth quarter. Meanwhile, the quarter-end position value increased by $41.75 million, reflecting both share additions and stock price movements.
Eversept Partners added 264,468 shares of Vera Therapeutics in the fourth quarter; the estimated transaction value was $9.39 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased in value by $73.99 million, reflecting both trading and stock price movement.
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.
